Safety of biologics in psoriasis

被引：107
作者：
Kamata, Masahiro [1 ]
Tada, Yayoi [1 ]
机构：
[1] Teikyo Univ, Dept Dermatol, Sch Med, Tokyo, Japan
来源：
JOURNAL OF DERMATOLOGY | 2018年 / 45卷 / 03期
关键词：
anti-interleukin-12; 23p40; antibody; biologics; interleukin-17; inhibitor; psoriasis; tumor necrosis factor- inhibitor; SEVERE PLAQUE PSORIASIS; NECROSIS-FACTOR ANTAGONIST; PLACEBO-CONTROLLED TRIAL; TO-SEVERE PSORIASIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; SERUM KL-6 LEVELS; RHEUMATOID-ARTHRITIS PATIENTS; RANDOMIZED CONTROLLED-TRIALS; B-VIRUS-INFECTION; OF-THE-LITERATURE;
D O I：
10.1111/1346-8138.14096
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor- inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti-IL-17A antibodies. Brodalumab is an anti-IL17RA antibody. In this review, we pick up topics which have drawn attention regarding the safety of biologics and discuss them with recent published work.
引用
收藏
页码：279 / 286
页数：8
相关论文
共 116 条
  • [1] Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors
    Aeberli, D
    Seitz, M
    Jüni, P
    Villiger, PM
    [J]. RHEUMATOLOGY, 2005, 44 (02) : 172 - 175
  • [2] Aeberli D, 2002, SWISS MED WKLY, V132, P414
  • [3] Detection and management of latent tuberculosis infections before biologic therapy for psoriasis
    Amerio, Paolo
    Amoruso, Giuseppe
    Bardazzi, Federico
    Campanati, Anna
    Cassano, Nicoletta
    Conti, Andrea
    Gisondi, Paolo
    Guarneri, Claudio
    Mazzotta, Annamaria
    Piaserico, Stefano
    Prestinari, Francesca
    Prignano, Francesca
    Zane, Cristina
    de Simone, Clara
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (04) : 305 - 311
  • [4] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Antoni, CE
    Kavanagh, A
    Kirkham, B
    Tutuncu, Z
    Burmester, GR
    Schneider, U
    Furst, DE
    Molitor, J
    Keystone, E
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, DJ
    Weisman, MH
    Kalden, JR
    Smolen, J
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (04): : 1227 - 1236
  • [5] Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography
    Armstrong, April W.
    Harskamp, Caitlin T.
    Ledo, Lynda
    Rogers, Jason H.
    Armstrong, Ehrin J.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (07) : 976 - 980
  • [6] Psoriasis and Hypertension Severity: Results from a Case-Control Study
    Armstrong, April W.
    Lin, Steven W.
    Chambers, Cynthia J.
    Sockolov, Mary E.
    Chin, David L.
    [J]. PLOS ONE, 2011, 6 (03):
  • [7] Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
    Asahina, Akihiko
    Nakagawa, Hidemi
    Etoh, Takafumi
    Ohtsuki, Mamitaro
    [J]. JOURNAL OF DERMATOLOGY, 2010, 37 (04) : 299 - 310
  • [8] Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
    Baeten, Dominique
    Sieper, Joachim
    Braun, Juergen
    Baraliakos, Xenofon
    Dougados, Maxime
    Emery, Paul
    Deodhar, Atul
    Porter, Brian
    Martin, Ruvie
    Andersson, Mats
    Mpofu, Shephard
    Richards, Hanno B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) : 2534 - 2548
  • [9] Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
    Bagnoli, Marina
    Canevari, Silvana
    Califano, Daniela
    Losito, Simona
    Di Maio, Massimo
    Raspagliesi, Francesco
    Carcangiu, Maria Luisa
    Toffoli, Giuseppe
    Cecchin, Erika
    Sorio, Roberto
    Canzonieri, Vincenzo
    Russo, Daniela
    Scognamiglio, Giosue
    Chiappetta, Gennaro
    Baldassarre, Gustavo
    Lorusso, Domenica
    Scambia, Giovanni
    Zannoni, Gian Franco
    Savarese, Antonella
    Carosi, Mariantonia
    Scollo, Paolo
    Breda, Enrico
    Murgia, Viviana
    Perrone, Francesco
    Pignata, Sandro
    De Cecco, Loris
    Mezzanzanica, Delia
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : 1137 - 1146
  • [10] Bardazzi F, 2014, J DTSCH DERMATOL GES, V12, P401, DOI [10.1111/ddg.12339, 10.1111/ddg.12339_suppl]
12345678910